ESTRO 2024 - Abstract Book

S2310

Clinical - Urology

ESTRO 2024

diagnosed with local and distant failure. CRFS rates at 2-yr and 5-yr were 29% ± 5% and 20 ± 5%, respectively, and the median CRFS time was 9 months (95% CI: 4-14). The 2-yr and 5-yr OS rates were 46% ± 6% and 33% ± 6%, respectively. Hematological toxicity developed following EBRT treatment is reported in Table 1. Thirty-one patients (43%) received neo-adjuvant chemotherapy before RC. Univariate analysis showed that neo-adjuvant chemotherapy did not exhibit a significant influence on either baseline or post-EBRT blood count values.

Figure 1. Local relapse-free rate

Table 1. Haematological toxicity (CTCAE version 5) post adjuvant external beam radiotherapy (0-24 months)

Grade 2

Grade 3

Grade 4

WBC<3.0-2.0

x10*9/L

WBC<2.0-1.0

x10*9/L

WBC<1.0

x10*9/L

Leukopenia (N=61)

6 (10)

0

0

ALC<0.8-0.5

x10*9/L

ALC<0.5-0.2

x10*9/L

ALC<0.2

x10*9/L

Lymphopenia (N=58)

20 (34)

30 (52)

5 (9)

ANC<1.5-1.0

x10*9/L

ANC<1.0-0.5

x10*9/L

ANC<0.5

x10*9/L

Neutropenia (N=58)

1 (2)

0

0

Thrombocytopenia (N=60)

PLT<75-50

x10*9/L

PLT<50-25

x10*9/L

PLT<25

x10*9/L

0

1 (2)

0